Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.
Journal: Clinical breast cancer
Published: February 19, 2026
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 19, 2023
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Journal: JAMA oncology
Published: December 01, 2022
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
Journal: Breast cancer research and treatment
Published: November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
Journal: JAMA oncology
Published: November 17, 2022
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 10, 2021
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 23, 2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Journal: The New England journal of medicine
Published: April 21, 2021
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 31, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 30, 2020
Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: September 09, 2018
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
Journal: The Annals of pharmacotherapy
Published: June 17, 2016
Last Updated: 09/26/2026